الصفحة 1 من عند 50 النتائج
TECHNICAL FIELD
The invention generally relates to the diagnosis and treatment of Alzheimer's disease. More specifically, it relates to the characterization and use of materials related to amyloid protein deposits associated with Alzheimer's disease, and to a specific DNA sequence encoding a novel
Alzheimer's disease is a degenerative disorder of the human brain. Clinically, it appears as a progressive dementia. Its histopathology is characterized by degeneration of neurons, gliosis, and the abnormal deposition of proteins in the brain. Proteinaceous deposits (called "amyloid") appear as
This invention relates to treatment of Alzheimer's disease.
The brains of persons having Alzheimer's disease and Down's syndrome and, to a far lesser extent, the brains of normal aged persons exhibit abnormal extracellular proteinaceous deposits, termed amyloid. Amyloid deposits are thought to be
BACKGROUND OF THE INVENTION
This invention was made during the course of work supported in part by the U.S. Government, and the Government has certain rights in the invention.
This invention relates to treatment of Alzheimer's disease.
The brains of persons having Alzheimer's disease and Down's
FIELD OF THE PRESENT INVENTION
The present invention is directed to novel compounds and also to methods of treating at least one condition, disorder, or disease associated with amyloidosis using such compounds.
BACKGROUND OF THE PRESENT INVENTION
Amyloidosis refers to a collection of conditions,
BACKGROUND OF THE INVENTION
A peptide of 42 to 43 residues known as the .beta.-amyloid peptide (.beta./A4) has been implicated in Alzheimers's disease and Down's syndrome. Researchers hypothesize that abnormal accumulation of this 4 Kd protein in the brain is due to cleavage of a larger precursor
FIELD OF THE INVENTION
The invention relates to methods and compositions for inhibiting certain aspartyl proteases. More particularly it relates to methods and compounds for inhibiting the enzymatic activity of secretases involved in converting amyloid precursor protein to amyloid-.beta. peptide.
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common form of both senile and presenile dementia in the world and is recognized clinically as relentlessly progressive dementia that presents with increasing loss of memory, intellectual function and disturbances in speech (Merritt,
The present invention relates to catalytic monoclonal antibodies, in particular with protease activity, for the selective lysis of the protein component of plaques and aggregates related to pathological conditions.
Alzheimer's Disease
Alzheimer's disease (AD) is a degenerative disease which affects
STATEMENT REGARDING FEDERALLY-SPONSORED R&D
Not applicable.
REFERENCE TO MICROFICHE APPENDIX
Not applicable.
FIELD OF THE INVENTION
The present invention is directed to the field of Alzheimer's disease. In particular, the present invention provides a novel aspartyl protease involved in the
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
FIELD OF THE INVENTION
The present invention relates to purification of mammalian enzymes and more particularly to the purification of human amyloidin protease, the identification of the gene encoding the protease, the identification of inhibitors of this protease, and various uses